Naporafenib

DB18865InvestigationalSmall molecule

Naporafenib is under investigation in clinical trial NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With Nras-mutant Melanoma (SEACRAFT-2)).

Chemical structure of Naporafenib
Formula / weight
C25H25F3N4O4 · 502.494 g/mol (avg)
Also known as
4-pyridinecarboxamide, n-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)- · N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamide · Pan-raf inhibitor lxh254
Code names
ERAS-254 · LXH-254

Resolves to

Compound
UNII15JL80DG6HCAS1800398-38-2ChEMBLCHEMBL4583691
Structure
InChIKeyUEPXBTCUIIGYCY-UHFFFAOYSA-NSMILESCC1=CC=C(NC(=O)C2=CC=NC(=C2)C(F)(F)F)C=C1C1=CC(OCCO)=NC(=C1)N1CCOCC1
Targets
P04049RAF1

What you can answer from here — as of May 26, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Naporafenib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In